This article has been updated to include comments from the company's analyst conference call.

NEW YORK (GenomeWeb) – Exact Sciences reported before the opening of the market on Tuesday that its fourth quarter revenues rose 144 percent, due to a 114 percent uptick year over year in the number of Cologuard colon cancer tests it completed during the quarter.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.